Peritoneal cancer
Drug research and approvals for peritoneal cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 215 studies of peritoneal cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 21 drug trials for it since 2013, FDA has 12 approved and 4 open orphan designations naming it, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 215
- Trials authorized in Canada: 21
- FDA orphan approvals: 12
- EU medicines: 4
- A KRAS Inhibitor in Participants With Advanced Solid TumorsNCT07912593 · Phase 1 / Phase 2 · Ensem Therapeutics · starts Oct 22, 2026
- Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian,…NCT07896421 · Not reported · AbbVie · starts Oct 21, 2026
- Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic LesionsNCT07883798 · Not reported · Affidea Nu-med Center of Oncological DIagnostics and Therapy · starts Oct 6, 2026
- Histotripsy for Peritoneal Tumour and Lymph Node: a Pilot StudyNCT07873619 · Not applicable · The University of Hong Kong · starts Dec 1, 2026
- Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced…NCT07855640 · Not reported · Zhejiang Cancer Hospital · starts Jul 1, 2026
- Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD)…NCT07851025 · Phase 3 · AstraZeneca · starts Sep 16, 2026
- Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial…NCT07816666 · Phase 3 · AstraZeneca · starts Sep 24, 2026
- FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III…NCT07815834 · Phase 3 · Fudan University · starts Oct 1, 2026
- Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)NCT07795749 · Phase 2 · University of California, Irvine · starts Aug 4, 2026
Approved 3
- BevacizumabVascular endothelial growth factor A inhibitor
- NiraparibPoly [ADP-ribose] polymerase 2 inhibitor
- Mirvetuximab soravtansineFolate receptor alpha binding agent
Phase 3 12 of 20
- CarboplatinDNA inhibitor
- PaclitaxelTubulin inhibitor
- CisplatinDNA inhibitor
- TopotecanDNA topoisomerase I inhibitor
- DocetaxelTubulin inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- RucaparibPARP 1, 2 and 3 inhibitor
- ErlotinibEpidermal growth factor receptor erbB1 inhibitor
- TamoxifenEstrogen receptor alpha modulator
- BinimetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor
- AlvimopanMu opioid receptor antagonist
Phase 2 12 of 74
- CyclophosphamideDNA inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- PembrolizumabProgrammed cell death protein 1 inhibitor
- OxaliplatinDNA inhibitor
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
- CapecitabineThymidylate synthase inhibitor
- GefitinibEpidermal growth factor receptor erbB1 inhibitor
- PemetrexedThymidylate synthase inhibitor
- PegfilgrastimGranulocyte colony stimulating factor receptor agonist
- Denileukin diftitoxElongation factor 2 inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- PazopanibMacrophage colony stimulating factor receptor inhibitor
Phase 1 or earlier 12 of 37
- Maveropepimut-s
- EpacadostatIndoleamine 2,3-dioxygenase inhibitor
- SS1(DSFV)-PE38Mesothelin binding agent
- QS-21
- AlemtuzumabCAMPATH-1 antigen inhibitor
- Etoposide phosphateDNA topoisomerase II alpha inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- ThiotepaDNA inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- Peginterferon alfa-2bInterferon alpha/beta receptor agonist
- VorinostatHistone deacetylase 1 inhibitor
How its trials ended
385 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 101 whose ending is known, 30% met their primary endpoint, 12% missed it and 58% stopped early.
- Completed, result not reported14137%
- Ongoing10327%
- Status unknown4010%
- Stopped: other or unclear328%
- Met its primary endpoint308%
- Stopped: enrollment or feasibility144%
- Missed its primary endpoint123%
- Stopped: lack of efficacy82%
- Stopped: funding31%
- Stopped: sponsor or business decision21%
| Aug 26, 2026 | A randomised, open-label, phase III study of torvutatug samrotecan with or without bevacizumab versus standard of care as second- or third-line maintenance…AZD5335 / Avastin / Vegzelma | AstraZeneca Pharmaceuticals | Pending |
| Aug 20, 2026 | A randomised, open-label, phase III study of torvutatug samrotecan in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance…Torvutatug samrotecan (AZD5335) / Avastin (bevacizumab) / Vegzelma (bevacizumab) | AstraZeneca Pharmaceuticals | Pending |
| Dec 23, 2025 | A phase 1b/2 open-label, multicenter study to evaluate the safety and efficacy of raludotatug deruxtecan with or without other anticancer investigational…MK-5909 (raludotatug deruxtecan (r-dxd)) / Keytruda / Bevacizumab / Paclitaxel… | Merck & Co. (MSD) | Ongoing |
| Jun 12, 2024 | A phase 1, first-in-human, open-label, dose-escalation and expansion study of IMGN151 (anti-fr antibody-drug conjugate) in adult patients with recurrent…IMGN151 | AbbVie | Ongoing |
| Jan 18, 2023 | A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced, platinum-resistant high-grade epithelial…Relacorilant (CORT125134) / Paclitaxel | Corcept Therapeutics | Ongoing |
| Nov 9, 2022 | Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy…Mirvetuximab soravtansine | AbbVie | Ongoing |
| Sep 29, 2022 | Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate…Mirvetuximab soravtansine (IMGN853) | AbbVie | Ongoing |
| Feb 11, 2022 | Piccolo: a phase 2, single arm study of mirvetuximab soravtansine in recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or…Mirvetuximab soravtansine (IMGN853) | AbbVie | Closed |
| Oct 18, 2021 | A phase 3, multicenter, open-label, randomized study of nemvaleukin alfa in combination with pembrolizumab versus investigator's choice chemotherapy in…Alks 4230 / Keytruda | Mural Oncology | Ongoing |
| Feb 19, 2020 | Mirasol: a randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial…Mirvetuximab soravtansine (IMGN853) | AbbVie | Ongoing |
| Nov 14, 2022 | ElahereTreatment of adult patients with folate receptor-alpha (FR?) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary… | ImmunoGen, Inc. | Approved |
| May 8, 2020 | LynparzaLynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian,… | AstraZeneca Pharmaceuticals LP | Approved |
| May 8, 2020 | LynparzaLynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian,… | AstraZeneca Pharmaceuticals LP | Approved |
| May 8, 2020 | LynparzaLynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian,… | AstraZeneca Pharmaceuticals LP | Approved |
| Apr 29, 2020 | ZejulaZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal… | GlaxoSmithKline, LLC. | Approved |
| Oct 23, 2019 | ZejulaZEJULA? is indicated for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been… | GlaxoSmithKline, LLC. | Approved |
| Dec 19, 2018 | LynparzaLynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic… | AstraZeneca Pharmaceuticals LP | Approved |
| Apr 6, 2018 | RubracaFor the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in… | pharma& | Approved |
| Aug 17, 2017 | LynparzaMaintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a… | AstraZeneca Pharmaceuticals LP | Approved |
| Aug 17, 2017 | LynparzaMaintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a… | AstraZeneca Pharmaceuticals LP | Approved |
| Aug 17, 2017 | LynparzaMaintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a… | AstraZeneca Pharmaceuticals LP | Approved |
| Mar 27, 2017 | ZejulaIndicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who… | GlaxoSmithKline, LLC. | Approved |
| Mar 2, 2026 | RezatapoptTreatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer | PMV Pharmaceuticals, Inc. | Designated |
| Aug 27, 2024 | N-[5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluor…Treatment of AT-rich interactive domain-containing protein 1a (ARID1a)-deficient ovarian cancer, fallopian tube cancer, and primary… | Nuvectis Pharma, Inc. | Designated |
| Feb 15, 2024 | GleolanDiagnostic for the management of ovarian, fallopian tube, and primary peritoneal cancer | NX Development Corp. | Designated |
| Nov 14, 2024 | ElahereMirvetuximab soravtansine · orphan | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Jul 26, 2024 | AvziviBevacizumab · biosimilar | FGK Representative Service GmbH | EMA ↗ |
| May 23, 2018 | RubracaRucaparib | pharmaand GmbH | EMA ↗ |
| Nov 16, 2017 | ZejulaNiraparib · orphan | GlaxoSmithKline Trading Services Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA